Pseudomonas aeruginosa is a commonly isolated pathogen in adults with cystic fibrosis (CF). Antimicrobial resistance is an escalating problem due to chronic colonization and frequent antimicrobial exposure. Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) exhibit promising activity against antimicrobial resistant organisms, including P. aeruginosa. A retrospective review was conducted comparing the in vitro activities of C/T and CZA against 42 P. aeruginosa isolates from the respiratory tract of 32 adults with CF. The first isolate per patient per year that underwent susceptibility testing for C/T, CZA, and colistin was included. C/T was more susceptible than CZA (60% versus 43%). Thirty-eight (90%) isolates were considered highly drug resistant and demonstrated higher C/T susceptibilities compared to CZA (55% versus 45%). These results suggest using C/T while awaiting susceptibilities when standard antipseudomonal agents cannot be used.

铜绿假单胞菌是成年人患有囊性纤维化（CF）的一种常见病原体。由于慢性定植和频繁的抗菌暴露，抗菌素耐药性是一个逐步升级的问题。头孢唑烷-他唑巴坦（C / T）和头孢他啶-avibactam（CZA）对包括铜绿假单胞菌在内的抗药性生物体显示出有希望的活性。进行了回顾性比较，比较了C / T和CZA对42种铜绿假单胞菌的体外活性从32名患有CF的成人的呼吸道中分离出来。包括每位患者每年接受C / T，CZA和粘菌素敏感性测试的首个分离株。C / T比CZA更易感（60％比43％）。与CZA相比，三十八（90％）个分离株被认为具有高度的耐药性，并显示出更高的C / T敏感性（55％对45％）。这些结果表明，当无法使用标准的抗假单胞菌药物时，在等待药敏试验的同时使用C / T。